Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92


Decision analysis, economic evaluation, and newborn screening: challenges and opportunities.

Prosser LA, Grosse SD, Kemper AR, Tarini BA, Perrin JM.

Genet Med. 2012 Apr 5. doi: 10.1038/gim.2012.24. [Epub ahead of print]


Projected cost-effectiveness of statewide universal newborn hearing screening.

Keren R, Helfand M, Homer C, McPhillips H, Lieu TA.

Pediatrics. 2002 Nov;110(5):855-64.


The use of economic evaluations in NHS decision-making: a review and empirical investigation.

Williams I, McIver S, Moore D, Bryan S.

Health Technol Assess. 2008 Apr;12(7):iii, ix-x, 1-175.


Screening of the hearing of newborns - Update.

Schnell-Inderst P, Kunze S, Hessel F, Grill E, Siebert U, Nickisch A, von Voß H, Wasem J.

GMS Health Technol Assess. 2006 Nov 27;2:Doc20.


Economic evaluation and mental health: sparse past. fertile future?

Knapp M.

J Ment Health Policy Econ. 1999 Dec 1;2(4):163-167.


Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis.

Knowles R, Griebsch I, Dezateux C, Brown J, Bull C, Wren C.

Health Technol Assess. 2005 Nov;9(44):1-152, iii-iv. Review.


Cost-Effectiveness and Affordability of Interventions, Policies, and Platforms for the Prevention and Treatment of Mental, Neurological, and Substance Use Disorders.

Levin C, Chisholm D.

In: Patel V, Chisholm D, Dua T, Laxminarayan R, Medina-Mora ME, editors. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, Third Edition (Volume 4). Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2016 Mar 14. Chapter 12.


The effectiveness of web-based programs on the reduction of childhood obesity in school-aged children: A systematic review.

Antwi F, Fazylova N, Garcon MC, Lopez L, Rubiano R, Slyer JT.

JBI Libr Syst Rev. 2012;10(42 Suppl):1-14.


The cost-effectiveness of universal newborn screening for bilateral permanent congenital hearing impairment: systematic review.

Colgan S, Gold L, Wirth K, Ching T, Poulakis Z, Rickards F, Wake M.

Acad Pediatr. 2012 May-Jun;12(3):171-80. doi: 10.1016/j.acap.2012.02.002. Review.


Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Heather EM, Payne K, Harrison M, Symmons DP.

Pharmacoeconomics. 2014 Feb;32(2):109-34. doi: 10.1007/s40273-013-0120-z. Review.


A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.


Decision-making process for conditions nominated to the recommended uniform screening panel: statement of the US Department of Health and Human Services Secretary's Advisory Committee on Heritable Disorders in Newborns and Children.

Kemper AR, Green NS, Calonge N, Lam WK, Comeau AM, Goldenberg AJ, Ojodu J, Prosser LA, Tanksley S, Bocchini JA Jr.

Genet Med. 2014 Feb;16(2):183-7. doi: 10.1038/gim.2013.98. Epub 2013 Aug 1.


Current practice, accuracy, effectiveness and cost-effectiveness of the school entry hearing screen.

Bamford J, Fortnum H, Bristow K, Smith J, Vamvakas G, Davies L, Taylor R, Watkin P, Fonseca S, Davis A, Hind S.

Health Technol Assess. 2007 Aug;11(32):1-168, iii-iv. Review.


Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation.

Rodgers M, McKenna C, Palmer S, Chambers D, Van Hout S, Golder S, Pepper C, Todd D, Woolacott N.

Health Technol Assess. 2008 Nov;12(34):iii-iv, xi-xiii, 1-198. Review.


A qualitative systematic review of internal and external influences on shared decision-making in all health care settings.

Truglio-Londrigan M, Slyer JT, Singleton JK, Worral P.

JBI Libr Syst Rev. 2012;10(58):4633-4646.


Exploring barriers to long-term follow-up in newborn screening programs.

Hoff T, Hoyt A, Therrell B, Ayoob M.

Genet Med. 2006 Sep;8(9):563-70.


Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.


Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.

Blau J, Hoestlandt C, D Clark A, Baxter L, Felix Garcia AG, Mounaud B, Mosina L.

Vaccine. 2015 May 7;33 Suppl 1:A34-9. doi: 10.1016/j.vaccine.2014.12.073.


Cost of disorders of the brain in Europe 2010.

Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van den Bergh P, van Os J, Vos P, Xu W, Wittchen HU, Jönsson B, Olesen J; CDBE2010Study Group.

Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79. doi: 10.1016/j.euroneuro.2011.08.008. Epub 2011 Sep 15. Erratum in: Eur Neuropsychopharmacol. 2012 Mar;22(3):237-8. den Bergh, Peter Van [corrected to Van den Bergh, Peter].


Supplemental Content

Support Center